Clovis Oncology Enterprise Value:
793.74M for May 20, 2013Clovis Oncology Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| May 20, 2013 | 793.74M |
| May 17, 2013 | 823.63M |
| May 16, 2013 | 818.91M |
| May 15, 2013 | 834.64M |
| May 14, 2013 | 898.88M |
| May 13, 2013 | 851.69M |
| May 10, 2013 | 813.14M |
| May 9, 2013 | 811.57M |
| May 8, 2013 | 828.88M |
| May 7, 2013 | 721.38M |
| May 6, 2013 | 853.00M |
| May 3, 2013 | 849.85M |
| May 2, 2013 | 835.95M |
| May 1, 2013 | 825.99M |
| April 30, 2013 | 837.00M |
| April 29, 2013 | 838.84M |
| April 26, 2013 | 848.01M |
| April 25, 2013 | 832.55M |
| April 24, 2013 | 825.94M |
| April 23, 2013 | 814.98M |
| April 22, 2013 | 716.92M |
| April 19, 2013 | 694.90M |
| April 18, 2013 | 694.64M |
| April 17, 2013 | 662.12M |
| April 16, 2013 | 670.78M |
| April 15, 2013 | 640.63M |
| April 12, 2013 | 666.84M |
| April 11, 2013 | 667.11M |
| April 10, 2013 | 666.58M |
| April 9, 2013 | 642.20M |
| April 8, 2013 | 630.14M |
| April 5, 2013 | 613.88M |
| April 4, 2013 | 593.69M |
| April 3, 2013 | 594.74M |
| April 2, 2013 | 609.69M |
| April 1, 2013 | 573.24M |
| March 28, 2013 | 607.50M |
| March 27, 2013 | 603.31M |
| March 26, 2013 | 601.73M |
| March 25, 2013 | 594.66M |
| March 22, 2013 | 595.97M |
| March 21, 2013 | 588.89M |
| March 20, 2013 | 583.38M |
| March 19, 2013 | 579.98M |
| March 18, 2013 | 614.84M |
| March 15, 2013 | 587.32M |
| March 14, 2013 | 595.70M |
| March 13, 2013 | 599.11M |
| March 12, 2013 | 578.14M |
| March 11, 2013 | 575.52M |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
CLVS Enterprise Value Benchmarks
| Companies | |
|---|---|
| Coronado Biosciences | 241.30M |
| Halozyme Therapeutics | 830.22M |
| Infinity Pharmaceuticals | 865.40M |
CLVS Enterprise Value Rankings
| Overall |
71st percentile 2290 of 8002 |
| Sector |
71st percentile 198 of 684 in Healthcare |
| Industry |
81st percentile 46 of 248 in Biotechnology |
CLVS Enterprise Value Range, Past 5 Years
| Minimum | 142.04M | Nov 16 2012 |
| Maximum | 898.88M | May 14 2013 |
| Average | 376.87M |
